2026 Q2 - tulosraportti
Vain PDF
60 päivää sitten
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 12.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 13.8. | ||
2026 Q1 - tulosraportti 12.5. | ||
2025 Q4 - tulosraportti 17.2. | ||
2025 Q3 - tulosraportti 11.11.2025 | ||
2025 Q2 - tulosraportti 12.8.2025 |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
·5.10.New analyses on terbinafine susceptibility and MOB-015 published in Journal of Fungi Riktigt positivt för oss.............The analyses are based on data from the previously completed North American Phase 3 study evaluating daily treatment with MOB-015 for 48 weeks. The analyses included 506 dermatophyte isolates from onychomycosis patients.
GPT Yes - this is actually really positive for Moberg, and I think it is more significant than it might first appear. The important thing is not just that terbinafine works, but what the analysis says about MOB-015 when there is reduced sensitivity/resistance. The strongest point in the result * 506 dermatophyte isolates were analyzed from the North American phase III study. * Only 3.2 % had an elevated MIC value (≥0.5 µg/ml), meaning the vast majority were still sensitive to terbinafine. * Among MOB-015 patients with evaluable results, 74.3 % achieved mycological cure. * Above all: MOB-015 provided mycological cure across the entire range of baseline terbinafine sensitivity. * Even among the three patients with elevated MIC, 2 out of 3 achieved mycological cure. Why I think this is important for MOB It strengthens a very good commercial narrative: Terbinafine resistance → problem for oral/topical terbinafine → MOB-015 can still work because the formulation delivers terbinafine locally through the nail. This does not mean the study proves that MOB-015 works against all terbinafine resistance — 3 patients are far too few for such a claim. But it is a very positive signal value. And it is particularly good that the results come from an already completed phase III study, rather than a small laboratory study. For the stock I would rank the news as: 🟢 Fundamentally positive: 8/10 🟢 Scientifically positive: 9/10 🟡 Direct revenue impact: low in the short term 🟡 Partner/marketing value: quite high Above all, it strengthens the argument that MOB-015 is not just “terbinafine in a lacquer”, but a formulation that potentially can solve the problem of getting sufficient concentrations of terbinafine into the nail. This can also be good ammunition for Moberg and their partners in marketing towards dermatologists, especially since resistance to antifungal drugs is receiving increasing attention. Moberg explicitly states that the results strengthen the scientific basis for MOB-015. And one thing I find extra interesting: this comes right after their EADV participation and before/around CPHI. It could therefore have greater significance for partner discussions than the press release itself implies. https://www.mdpi.com/2309-608X/12/10/739- ·28.9.Milan 6-8 October Congress/Vienna, 30 September-3 Oct Noticed that an employee (General Manager) from Taisho Pharma gave a thumbs up ahead of the Congress in Milan and Vienna on Moberg's Linkedin. Taisho sells over-the-counter products in Japan. Who knows, maybe some deal in the making at the Congress meeting. Japan and USA left and then they have agreements for the most crucial regions. https://www.taisho.co.jp/en/products/2019: Moberg Pharma signed an exclusive license agreement with Taisho for MOB-015 in Japan. * Taisho would finance development and registration as well as handle marketing, distribution and sales in Japan. * The agreement could provide Moberg with up to 50 million USD in milestone payments, including 5 million USD upon signing of the agreement. * March 2023: Taisho terminated the development of MOB-015 for strategic reasons and Moberg got back all rights in Japan. Moberg got to keep the already paid 5 million USD.
·25.9.Good grief how I look forward to 2026’Q4 and 2027’Q1 where hopefully there is/will be started up in some of the many potential markets. Quite a long wait - but am sure 2027 will be a fantastic equity year for Moberg
My 65.000 MOB shares are tucked so well into the mattress that I will definitely be sleeping soundly on top of them for the coming minimum 5 years - as long as the company does not lose its grip along the way. Just saying ☝️
·23.9.Moberg Pharma AB (OMX: MOB) announces that the sales representatives of the company's local partner Padagis Israel Agencies Ltd. today have initiated the marketing of Terclara® to dermatologists in Israel. The launch follows regulatory clearance from the Israeli Ministry of Health (MOH) for the first commercial batch. Israel is the first market where the drug MOB-015 (Terclara®) is launched outside the Nordics. As in the Nordics, the product is launched under Moberg Pharma's brand Terclara®. "We are very pleased to see Terclara® launched in Israel and to reach yet another important milestone in the international commercialization of our product. Padagis has carried out extensive preparations ahead of the launch and we look forward to supporting them as Terclara® is now introduced on the Israeli market," says Anna Ljung, CEO of Moberg Pharma. For further information, please contact: Anna Ljung, CEO, telephone: +46 8 522 307 01, email: anna.ljung@mobergpharma.se.From an economic perspective, this is not a huge event, which is why the share price is not exactly exploding today. What you can use this announcement for is to be confirmed in whether you believe in the messages the company overall is coming out with regarding rollout plans. This announcement hits the mark, which is positive - the crucial point now is the total EU rollout, 19 countries by the end of this year. Volatility in share price formation may occur by then, in both upward and downward directions, based on the announcements that are still pending - only time will tell☝️
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
Vain PDF
60 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·5.10.New analyses on terbinafine susceptibility and MOB-015 published in Journal of Fungi Riktigt positivt för oss.............The analyses are based on data from the previously completed North American Phase 3 study evaluating daily treatment with MOB-015 for 48 weeks. The analyses included 506 dermatophyte isolates from onychomycosis patients.GPT Yes - this is actually really positive for Moberg, and I think it is more significant than it might first appear. The important thing is not just that terbinafine works, but what the analysis says about MOB-015 when there is reduced sensitivity/resistance. The strongest point in the result * 506 dermatophyte isolates were analyzed from the North American phase III study. * Only 3.2 % had an elevated MIC value (≥0.5 µg/ml), meaning the vast majority were still sensitive to terbinafine. * Among MOB-015 patients with evaluable results, 74.3 % achieved mycological cure. * Above all: MOB-015 provided mycological cure across the entire range of baseline terbinafine sensitivity. * Even among the three patients with elevated MIC, 2 out of 3 achieved mycological cure. Why I think this is important for MOB It strengthens a very good commercial narrative: Terbinafine resistance → problem for oral/topical terbinafine → MOB-015 can still work because the formulation delivers terbinafine locally through the nail. This does not mean the study proves that MOB-015 works against all terbinafine resistance — 3 patients are far too few for such a claim. But it is a very positive signal value. And it is particularly good that the results come from an already completed phase III study, rather than a small laboratory study. For the stock I would rank the news as: 🟢 Fundamentally positive: 8/10 🟢 Scientifically positive: 9/10 🟡 Direct revenue impact: low in the short term 🟡 Partner/marketing value: quite high Above all, it strengthens the argument that MOB-015 is not just “terbinafine in a lacquer”, but a formulation that potentially can solve the problem of getting sufficient concentrations of terbinafine into the nail. This can also be good ammunition for Moberg and their partners in marketing towards dermatologists, especially since resistance to antifungal drugs is receiving increasing attention. Moberg explicitly states that the results strengthen the scientific basis for MOB-015. And one thing I find extra interesting: this comes right after their EADV participation and before/around CPHI. It could therefore have greater significance for partner discussions than the press release itself implies. https://www.mdpi.com/2309-608X/12/10/739
- ·28.9.Milan 6-8 October Congress/Vienna, 30 September-3 Oct Noticed that an employee (General Manager) from Taisho Pharma gave a thumbs up ahead of the Congress in Milan and Vienna on Moberg's Linkedin. Taisho sells over-the-counter products in Japan. Who knows, maybe some deal in the making at the Congress meeting. Japan and USA left and then they have agreements for the most crucial regions. https://www.taisho.co.jp/en/products/2019: Moberg Pharma signed an exclusive license agreement with Taisho for MOB-015 in Japan. * Taisho would finance development and registration as well as handle marketing, distribution and sales in Japan. * The agreement could provide Moberg with up to 50 million USD in milestone payments, including 5 million USD upon signing of the agreement. * March 2023: Taisho terminated the development of MOB-015 for strategic reasons and Moberg got back all rights in Japan. Moberg got to keep the already paid 5 million USD.
- ·25.9.Good grief how I look forward to 2026’Q4 and 2027’Q1 where hopefully there is/will be started up in some of the many potential markets. Quite a long wait - but am sure 2027 will be a fantastic equity year for MobergMy 65.000 MOB shares are tucked so well into the mattress that I will definitely be sleeping soundly on top of them for the coming minimum 5 years - as long as the company does not lose its grip along the way. Just saying ☝️
- ·23.9.Moberg Pharma AB (OMX: MOB) announces that the sales representatives of the company's local partner Padagis Israel Agencies Ltd. today have initiated the marketing of Terclara® to dermatologists in Israel. The launch follows regulatory clearance from the Israeli Ministry of Health (MOH) for the first commercial batch. Israel is the first market where the drug MOB-015 (Terclara®) is launched outside the Nordics. As in the Nordics, the product is launched under Moberg Pharma's brand Terclara®. "We are very pleased to see Terclara® launched in Israel and to reach yet another important milestone in the international commercialization of our product. Padagis has carried out extensive preparations ahead of the launch and we look forward to supporting them as Terclara® is now introduced on the Israeli market," says Anna Ljung, CEO of Moberg Pharma. For further information, please contact: Anna Ljung, CEO, telephone: +46 8 522 307 01, email: anna.ljung@mobergpharma.se.From an economic perspective, this is not a huge event, which is why the share price is not exactly exploding today. What you can use this announcement for is to be confirmed in whether you believe in the messages the company overall is coming out with regarding rollout plans. This announcement hits the mark, which is positive - the crucial point now is the total EU rollout, 19 countries by the end of this year. Volatility in share price formation may occur by then, in both upward and downward directions, based on the announcements that are still pending - only time will tell☝️
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 12.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 13.8. | ||
2026 Q1 - tulosraportti 12.5. | ||
2025 Q4 - tulosraportti 17.2. | ||
2025 Q3 - tulosraportti 11.11.2025 | ||
2025 Q2 - tulosraportti 12.8.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
Vain PDF
60 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 12.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 13.8. | ||
2026 Q1 - tulosraportti 12.5. | ||
2025 Q4 - tulosraportti 17.2. | ||
2025 Q3 - tulosraportti 11.11.2025 | ||
2025 Q2 - tulosraportti 12.8.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·5.10.New analyses on terbinafine susceptibility and MOB-015 published in Journal of Fungi Riktigt positivt för oss.............The analyses are based on data from the previously completed North American Phase 3 study evaluating daily treatment with MOB-015 for 48 weeks. The analyses included 506 dermatophyte isolates from onychomycosis patients.GPT Yes - this is actually really positive for Moberg, and I think it is more significant than it might first appear. The important thing is not just that terbinafine works, but what the analysis says about MOB-015 when there is reduced sensitivity/resistance. The strongest point in the result * 506 dermatophyte isolates were analyzed from the North American phase III study. * Only 3.2 % had an elevated MIC value (≥0.5 µg/ml), meaning the vast majority were still sensitive to terbinafine. * Among MOB-015 patients with evaluable results, 74.3 % achieved mycological cure. * Above all: MOB-015 provided mycological cure across the entire range of baseline terbinafine sensitivity. * Even among the three patients with elevated MIC, 2 out of 3 achieved mycological cure. Why I think this is important for MOB It strengthens a very good commercial narrative: Terbinafine resistance → problem for oral/topical terbinafine → MOB-015 can still work because the formulation delivers terbinafine locally through the nail. This does not mean the study proves that MOB-015 works against all terbinafine resistance — 3 patients are far too few for such a claim. But it is a very positive signal value. And it is particularly good that the results come from an already completed phase III study, rather than a small laboratory study. For the stock I would rank the news as: 🟢 Fundamentally positive: 8/10 🟢 Scientifically positive: 9/10 🟡 Direct revenue impact: low in the short term 🟡 Partner/marketing value: quite high Above all, it strengthens the argument that MOB-015 is not just “terbinafine in a lacquer”, but a formulation that potentially can solve the problem of getting sufficient concentrations of terbinafine into the nail. This can also be good ammunition for Moberg and their partners in marketing towards dermatologists, especially since resistance to antifungal drugs is receiving increasing attention. Moberg explicitly states that the results strengthen the scientific basis for MOB-015. And one thing I find extra interesting: this comes right after their EADV participation and before/around CPHI. It could therefore have greater significance for partner discussions than the press release itself implies. https://www.mdpi.com/2309-608X/12/10/739
- ·28.9.Milan 6-8 October Congress/Vienna, 30 September-3 Oct Noticed that an employee (General Manager) from Taisho Pharma gave a thumbs up ahead of the Congress in Milan and Vienna on Moberg's Linkedin. Taisho sells over-the-counter products in Japan. Who knows, maybe some deal in the making at the Congress meeting. Japan and USA left and then they have agreements for the most crucial regions. https://www.taisho.co.jp/en/products/2019: Moberg Pharma signed an exclusive license agreement with Taisho for MOB-015 in Japan. * Taisho would finance development and registration as well as handle marketing, distribution and sales in Japan. * The agreement could provide Moberg with up to 50 million USD in milestone payments, including 5 million USD upon signing of the agreement. * March 2023: Taisho terminated the development of MOB-015 for strategic reasons and Moberg got back all rights in Japan. Moberg got to keep the already paid 5 million USD.
- ·25.9.Good grief how I look forward to 2026’Q4 and 2027’Q1 where hopefully there is/will be started up in some of the many potential markets. Quite a long wait - but am sure 2027 will be a fantastic equity year for MobergMy 65.000 MOB shares are tucked so well into the mattress that I will definitely be sleeping soundly on top of them for the coming minimum 5 years - as long as the company does not lose its grip along the way. Just saying ☝️
- ·23.9.Moberg Pharma AB (OMX: MOB) announces that the sales representatives of the company's local partner Padagis Israel Agencies Ltd. today have initiated the marketing of Terclara® to dermatologists in Israel. The launch follows regulatory clearance from the Israeli Ministry of Health (MOH) for the first commercial batch. Israel is the first market where the drug MOB-015 (Terclara®) is launched outside the Nordics. As in the Nordics, the product is launched under Moberg Pharma's brand Terclara®. "We are very pleased to see Terclara® launched in Israel and to reach yet another important milestone in the international commercialization of our product. Padagis has carried out extensive preparations ahead of the launch and we look forward to supporting them as Terclara® is now introduced on the Israeli market," says Anna Ljung, CEO of Moberg Pharma. For further information, please contact: Anna Ljung, CEO, telephone: +46 8 522 307 01, email: anna.ljung@mobergpharma.se.From an economic perspective, this is not a huge event, which is why the share price is not exactly exploding today. What you can use this announcement for is to be confirmed in whether you believe in the messages the company overall is coming out with regarding rollout plans. This announcement hits the mark, which is positive - the crucial point now is the total EU rollout, 19 countries by the end of this year. Volatility in share price formation may occur by then, in both upward and downward directions, based on the announcements that are still pending - only time will tell☝️
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Välittäjätilasto
Dataa ei löytynyt